Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis

被引:0
|
作者
Spadaro, A
Taccari, E
Riccieri, V
Sensi, F
Scavalli, AS
Zoppini, A
机构
来源
REVUE DU RHUMATISME | 1997年 / 64卷 / 02期
关键词
interleukin-2; interleukin-6; rheumatoid factor; methotrexate; rheumatoid arthritis;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the effect of a 6-month treatment with low-dose MTX in 22 RA patients, with the purpose of investigating the relationship of sIL-2R and IL-6 serum chancres with those of class specific RFs. The patients with RA had higher serum levels of sIL-2R (p<0.00001) and IL-6 (p<0.0005) than healthy volunteers. We found that the levels of IgM-RF (p<0.0004), IgA-RF (p<0.002), IgG-RF (p<0.025), sIL-2R (p<0.017) and IL-6 (p<0.044), as well as the main clinical and laboratory variables, were significantly reduced in RA patients treated with low dose MTX for six months. The changes from baseline of IgM-RF correlated with those of IL-6 (p<0.023), suggesting that MTX may affect IL-6 and IgM-RF production in part by a common mechanism. In conclusion our results show that there is a relationship between IL-6 and IgM-RF changes from baseline during MTX therapy, but the hypothesis of a link between the effects of this drug on cytokine network and RF production needs further investigation.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 50 条
  • [1] Soluble interleukin-2-receptor and interleukin-6 changes during low-dose methotrexate treatment in rheumatoid arthritis
    Spadaro, A
    Riccieri, V
    Scavalli, AS
    Sensi, E
    Taccari, E
    Zoppini, A
    CLINICAL RHEUMATOLOGY, 1996, 15 (02) : 218 - 219
  • [2] ONE-YEAR TREATMENT WITH LOW-DOSE METHOTREXATE IN RHEUMATOID-ARTHRITIS - EFFECT ON CLASS-SPECIFIC RHEUMATOID FACTORS
    SPADARO, A
    RICCIERI, V
    SCAVALLI, AS
    TACCARI, E
    ZOPPINI, A
    CLINICAL RHEUMATOLOGY, 1993, 12 (03) : 357 - 360
  • [3] INTERLEUKIN-6 (IL-6) AND SOLUBLE IL-2 RECEPTOR LEVELS IN PATIENTS WITH RHEUMATOID-ARTHRITIS TREATED WITH LOW-DOSE ORAL METHOTREXATE
    CRILLY, A
    MCINNESS, IB
    MCDONALD, AG
    WATSON, J
    CAPELL, HA
    MADHOK, R
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (02) : 224 - 226
  • [4] Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
    Robak, T
    Gladalska, A
    Stepien, H
    Robak, E
    MEDIATORS OF INFLAMMATION, 1998, 7 (05) : 347 - 353
  • [5] Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: Correlations with clinical and laboratory parameters
    Spadaro, A
    Taccari, E
    Riccieri, V
    Sensi, F
    Scavalli, AS
    Zoppini, A
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (04) : 413 - 416
  • [6] Tocilizumab: An Interleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis
    Plushner, Susyn L.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (11) : 1660 - 1668
  • [7] Soluble interleukin-2 receptor and interleukin-6 levels: Evaluation during cyclosporin a and methotrexate treatment in psoriatic arthritis
    Spadaro, A
    Taccari, E
    Sensi, F
    Riccieri, V
    Scavalli, AS
    Zoppini, A
    CLINICAL RHEUMATOLOGY, 1998, 17 (01) : 83 - 85
  • [8] Soluble interleukin-2 receptor and interleukin-6 levels: Evaluation during cyclosporin a and methotrexate treatment in psoriatic arthritis
    A. Spadaro
    E. Taccari
    F. Sensi
    V. Riccieri
    A. Sili Scavalli
    A. Zoppini
    Clinical Rheumatology, 1998, 17 : 83 - 85
  • [9] Interleukin-6, soluble interleukin-2 receptor and soluble interleukin-6 receptor in the sera of patients with different histological patterns of rheumatoid synovitis
    Klimiuk, PA
    Sierakowski, S
    Latosiewicz, R
    Cylwik, JP
    Cylwik, B
    Skowronski, J
    Chwiecko, J
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (01) : 63 - 69
  • [10] INTERLEUKIN-6 LEVELS DURING THERAPY WITH METHOTREXATE OR AZATHIOPRINE FOR RHEUMATOID-ARTHRITIS
    BARRERA, P
    SAUERWEIN, RW
    BOERBOOMS, AMT
    VANDEPUTTE, LBA
    VANDERMEER, JWM
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S307 - S307